Clinical Trial Update: A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of AK117/AK112 for metastatic and locally advanced triple-negative breast cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• AK112
• AK117 (AK117)

Snippet

Sponsor: Akeso | Conditions: Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING